Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary)
- Indications Carcinoma; Neuroendocrine tumours
- Focus Adverse reactions
- Acronyms EVINEC
- 05 Mar 2019 Planned End Date changed from 1 Feb 2019 to 1 Dec 2019.
- 05 Mar 2019 Planned primary completion date changed from 1 Nov 2018 to 1 Sep 2019.
- 31 Aug 2018 Biomarkers information updated